BridgeBio Oncology Therapeutics (BBOT) Securities (2024 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Securities of $336.2 million for Q1 2026, up 656.26% sequentially from $44.5 million in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Securities (2024 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Securities for 3 years, with the latest figure at $336.2 million in Q1 2026.

Quarterly Securities changed N/A year-over-year to $336.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $336.2 million (changed N/A YoY) and the FY2025 annual result came in at $44.5 million, up 656.64% from the prior year.
Securities advanced to $336.2 million in Q1 2026 per BBOT's latest filing, from $44.5 million in the prior quarter.
Over five years, Securities peaked at $336.2 million in Q1 2026 and troughed at $5.9 million in Q4 2024.
A 3-year average of $128.9 million and a median of $44.5 million in 2025 frame the typical range for Securities.
The widest YoY moves for Securities: up 656.64% in 2025, down 656.64% in 2025.
Over 3 years, Securities stood at $5.9 million in 2024, then surged by 656.64% to $44.5 million in 2025, then surged by 656.26% to $336.2 million in 2026.
According to Business Quant data, Securities over the past three periods registered $336.2 million, $44.5 million, and $5.9 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Securities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-	290.07 Mn

Download Data